A report offers insights into key trends in the CMO sector
This article was published in our sister publication, The Small Molecule Manufacturer, which celebrates the field of small molecule drug development and manufacturing with interviews and articles focusing on success stories, equipment, and new processing techniques.
Growing demand for medicines, the capital-intensive nature of drug manufacturing, and complex requirements are leading pharma companies to become increasingly reliant on CDMOs. In turn, this has contributed to increased profitability for the outsourcing sector. In 2019, the CDMO market was valued at $150.7 billion and is expected to reach $246.2 billion by 2025 (1). In many cases, pharma companies prefer to spend on in-house R&D technologies and then invest in outsourcing partners with state-of-the-art facilities to take care of the manufacturing side.
The report covers a number of interesting topic areas.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.